Johnson & Johnson Gross Profit Growth & History (JNJ)
Johnson & Johnson's gross profit was $63.94B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $63.94B | $2.59B | +4.22% |
| 2024 | 2024-12-29 | $61.35B | $2.74B | +4.68% |
| 2023 | 2023-12-31 | $58.61B | $3.21B | +5.80% |
| 2022 | 2023-01-01 | $55.39B | $56.0M | +0.10% |
| 2021 | 2022-01-02 | $55.34B | $1.18B | +2.18% |
| 2020 | 2021-01-04 | $54.16B | −$346.0M | −0.63% |
| 2019 | 2019-12-29 | $54.50B | $13.0M | +0.02% |
| 2018 | 2018-12-30 | $54.49B | $3.48B | +6.82% |
| 2017 | 2017-12-31 | $51.01B | $910.0M | +1.82% |
| 2016 | 2017-01-01 | $50.10B | $1.56B | +3.22% |
| 2015 | 2016-01-03 | $48.54B | −$3.05B | −5.91% |
| 2014 | 2014-12-28 | $51.59B | $2.62B | +5.34% |
| 2013 | 2013-12-29 | $48.97B | $3.40B | +7.47% |
| 2012 | 2012-12-30 | $45.57B | $896.0M | +2.01% |
| 2011 | 2012-01-01 | $44.67B | $1.88B | +4.38% |
| 2010 | 2011-01-02 | $42.80B | −$655.0M | −1.51% |
| 2009 | 2010-01-03 | $43.45B | −$1.79B | −3.95% |
| 2008 | 2008-12-28 | $45.24B | $1.89B | +4.37% |
| 2007 | 2007-12-30 | $43.34B | — | — |
Johnson & Johnson quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $17.26B | $1.14B | +7.10% |
| Q1 2026 | 2026-03-29 | $15.96B | $1.42B | +9.77% |
| Q4 2025 | 2025-12-28 | $16.60B | $1.20B | +7.82% |
| Q3 2025 | 2025-09-28 | $16.69B | $1.18B | +7.62% |
| Q2 2025 | 2025-06-29 | $16.11B | $537.0M | +3.45% |
| Q1 2025 | 2025-03-30 | $14.54B | −$336.0M | −2.26% |
| Q4 2024 | 2024-12-29 | $15.39B | $795.0M | +5.45% |
| Q3 2024 | 2024-09-29 | $15.51B | $763.0M | +5.17% |
| Q2 2024 | 2024-06-30 | $15.58B | $521.0M | +3.46% |
| Q1 2024 | 2024-03-31 | $14.87B | $665.0M | +4.68% |
| Q4 2023 | 2023-12-31 | $14.60B | $742.0M | +5.36% |
| Q3 2023 | 2023-10-01 | $14.74B | $921.0M | +6.66% |
| Q2 2023 | 2023-07-02 | $15.06B | $1.16B | +8.38% |
| Q1 2023 | 2023-04-02 | $14.21B | $385.0M | +2.79% |
| Q4 2022 | 2023-01-01 | $13.86B | $5.59B | +67.59% |
| Q3 2022 | 2022-10-02 | $13.82B | −$2.26B | −14.07% |
| Q2 2022 | 2022-07-03 | $13.89B | −$1.83B | −11.65% |
| Q1 2022 | 2022-04-03 | $13.82B | −$1.44B | −9.41% |
| Q4 2021 | 2022-01-02 | $8.27B | −$6.39B | −43.61% |
| Q3 2021 | 2021-10-03 | $16.09B | $1.98B | +14.02% |
| Q2 2021 | 2021-07-04 | $15.72B | $3.97B | +33.75% |
| Q1 2021 | 2021-04-04 | $15.26B | $1.63B | +11.95% |
| Q4 2020 | 2021-01-04 | $14.66B | $1.05B | +7.70% |
| Q3 2020 | 2020-09-27 | $14.11B | $248.0M | +1.79% |
| Q2 2020 | 2020-06-28 | $11.76B | −$1.86B | −13.69% |
| Q1 2020 | 2020-03-29 | $13.63B | $223.0M | +1.66% |
| Q4 2019 | 2019-12-29 | $13.61B | $180.0M | +1.34% |
| Q3 2019 | 2019-09-29 | $13.86B | $103.0M | +0.75% |
| Q2 2019 | 2019-06-30 | $13.62B | −$281.0M | −2.02% |
| Q1 2019 | 2019-03-31 | $13.41B | $11.0M | +0.08% |
| Q4 2018 | 2018-12-30 | $13.43B | $497.0M | +3.84% |
| Q3 2018 | 2018-09-30 | $13.76B | $1.03B | +8.13% |
| Q2 2018 | 2018-07-01 | $13.90B | $910.0M | +7.00% |
| Q1 2018 | 2018-04-01 | $13.39B | $1.04B | +8.40% |
| Q4 2017 | 2017-12-31 | $12.94B | $364.0M | +2.90% |
| Q3 2017 | 2017-10-01 | $12.72B | $391.0M | +3.17% |
| Q2 2017 | 2017-07-02 | $12.99B | −$153.0M | −1.16% |
| Q1 2017 | 2017-04-02 | $12.36B | $204.0M | +1.68% |
| Q4 2016 | 2017-01-01 | $12.57B | $434.0M | +3.58% |
| Q3 2016 | 2016-10-02 | $12.33B | $456.0M | +3.84% |
| Q2 2016 | 2016-07-03 | $13.15B | $716.0M | +5.76% |
| Q1 2016 | 2016-04-03 | $12.15B | $61.0M | +0.50% |
| Q4 2015 | 2016-01-03 | $12.14B | −$263.0M | −2.12% |
| Q3 2015 | 2015-09-27 | $11.88B | −$1.19B | −9.11% |
| Q2 2015 | 2015-06-28 | $12.43B | −$1.03B | −7.62% |
| Q1 2015 | 2015-03-29 | $12.09B | −$568.0M | −4.49% |
| Q4 2014 | 2014-12-28 | $12.40B | $1.0M | +0.01% |
| Q3 2014 | 2014-09-28 | $13.07B | $837.0M | +6.84% |
| Q2 2014 | 2014-06-29 | $13.46B | $1.07B | +8.62% |
| Q1 2014 | 2014-03-30 | $12.66B | $709.0M | +5.93% |
| Q4 2013 | 2013-12-29 | $12.40B | $845.0M | +7.31% |
| Q3 2013 | 2013-09-29 | $12.23B | $776.0M | +6.77% |
| Q2 2013 | 2013-06-30 | $12.39B | $1.06B | +9.32% |
| Q1 2013 | 2013-03-31 | $11.95B | $727.0M | +6.48% |
| Q4 2012 | 2012-12-30 | $11.55B | $638.0M | +5.84% |
| Q3 2012 | 2012-09-30 | $11.46B | $522.0M | +4.77% |
| Q2 2012 | 2012-07-01 | $11.33B | −$93.0M | −0.81% |
| Q1 2012 | 2012-04-01 | $11.22B | −$171.0M | −1.50% |
| Q4 2011 | 2012-01-01 | $10.92B | $313.0M | +2.95% |
| Q3 2011 | 2011-10-02 | $10.93B | $545.0M | +5.25% |
| Q2 2011 | 2011-07-03 | $11.43B | $725.0M | +6.78% |
| Q1 2011 | 2011-04-03 | $11.39B | $292.0M | +2.63% |
| Q4 2010 | 2011-01-02 | $10.60B | −$635.0M | −5.65% |
| Q3 2010 | 2010-10-03 | $10.39B | −$259.0M | −2.43% |
| Q2 2010 | 2010-07-04 | $10.70B | −$89.0M | −0.82% |
| Q1 2010 | 2010-04-04 | $11.10B | $328.0M | +3.04% |
| Q4 2009 | 2010-01-03 | $11.24B | — | — |
| Q3 2009 | 2009-09-27 | $10.65B | −$500.0M | −4.49% |
| Q2 2009 | 2009-06-28 | $10.79B | −$910.0M | −7.78% |
| Q1 2009 | 2009-03-29 | $10.78B | — | — |
| Q3 2008 | 2008-09-28 | $11.15B | — | — |
| Q2 2008 | 2008-06-29 | $11.70B | — | — |
Johnson & Johnson gross profit trends
Over the last five fiscal years, Johnson & Johnson's gross profit increased from $54.16B to $63.94B, a change of $9.78B. The latest reported quarter, Q2 2026, shows $17.26B.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...